nidНефрология и диализNephrology and Dialysis1680-44222618-9801Российское диализное обществоnid-3754Research ArticleМАТЕРИАЛЫ III МЕЖДУНАРОДНОГО СЕМИНАРА ПО НЕФРОЛОГИИПроблемы лечения перитонитов, осложняющих хронический перитонеальный диализChallenges of managing chronic peritoneal dialysis-associated peritonitisЛаураК. ТройдлLauraK. Troidlenoemail@neicon.ruАланС. КлигерAlanS. Kligernoemail@neicon.ruФредрикО. ФинкелстейнFredricO. Finkelsteinnoemail@neicon.ruОтделение ПАПД, Почечный научно-исследовательский институт, Медицинская школа Йельского Университета, Нью Хевен, Штат Конектикут, СШАРоссияNew Haven CAPD, Renal Research Institute Yale University School of Medicine New Haven, Connecticut. U.S.ARussian Federation20002806202524273276Copyright © Лаура К.Т., Алан С.К., Фредрик О.Ф., 20252025Лаура К.Т., Алан С.К., Фредрик О.Ф.Laura K.T., Alan S.K., Fredric O.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephro.ru/jour/article/view/3754

Несмотря на значительный прогресс в области терапевтической эффективности и техники перитонеального диализа (ППД), наиболее частым осложнением этого вида заместительной почечной терапии остаются перитониты. В то время как, по данным ряда авторов, их число заметно снизилось, другие исследователи по-прежнему отмечают высокую частоту этого осложнения. Фактически перитониты являются главной причиной коморбидности и прекращения перитонеального диализа [1]. Более того, недавно опубликованы сообщения, в которых подчеркивается связь между перитонитами и смертностью [2, 3]. И в новом тысячелетии проблема диализных перитонитов порождает ряд вопросов. Один из них касается их эмпирической терапии и обоснования ее стратегии. Второй - антибактериальной терапии у больных, получающих ночной циклический перитонеальный диализ, используемый все чаще в связи с необходимостью поддержания адекватных диализных клиренсов. Третий вопрос - каковы факторы риска перитонитов? Наконец, известно, что грамотрицательные перитониты прогностически тяжелее грамположительных. В связи с этим возникает вопрос: что мы знаем об этиологии грамотрицательных перитонитов? В какой степени сам катетер способствует развитию перитонитов? * Перевод А.М. Андрусева

ХПНлечение ПАПДдиализные перитонитывозбудителилечениеReferencesBurkart J., Schreiber M., TaborT., Korbet S., Stallard R. and PD Collaborative Group. Prospective. multicenter evaluation of patient transfer from PD to HU in 1995 (Abstract). Pent Dial Int 1996; 16 (Suppl 2); 66.Burkart J., Schreiber M., TaborT., Korbet S., Stallard R. and PD Collaborative Group. Prospective. multicenter evaluation of patient transfer from PD to HU in 1995 (Abstract). Pent Dial Int 1996; 16 (Suppl 2); 66.Fried L.F., Bernardini J., Johnston J.R., Piraino B. Peritonitis influences mortality in peritoneal dialysis patients. J am Soc Nephrol 1996; 7: 2176-82.Fried L.F., Bernardini J., Johnston J.R., Piraino B. Peritonitis influences mortality in peritoneal dialysis patients. J am Soc Nephrol 1996; 7: 2176-82.Giorban-Brennan N., Troidle L., Kliger A., Finkel.stein F.O. Peritonitis and its relationship with death in a large CPD cohort (Abstract). Perit Dial Int 1999; 19 (Suppl 1): S31.Giorban-Brennan N., Troidle L., Kliger A., Finkel.stein F.O. Peritonitis and its relationship with death in a large CPD cohort (Abstract). Perit Dial Int 1999; 19 (Suppl 1): S31.Ad Hoc Advisory Committee on Peritonitis Management. Peritoneal dialysis-related peritonitis treatment recommendations: 1993 update. Perit Dial Int 1993; 13: 14-28.Ad Hoc Advisory Committee on Peritonitis Management. Peritoneal dialysis-related peritonitis treatment recommendations: 1993 update. Perit Dial Int 1993; 13: 14-28.Vas S. Treatment of peritonitis. Perit Dial Int 1994; 14 (Suppl 3): S49-55.Vas S. Treatment of peritonitis. Perit Dial Int 1994; 14 (Suppl 3): S49-55.Troidle L., Kliger AS., Gorban-Brennan N., Fikrig M., Golden M., Finkelstein F.O. Nine episodes of CPD-associated peritonitis with vancomycin resistant enterococci. Kidney Int 1996; 50: 1368-72.Troidle L., Kliger AS., Gorban-Brennan N., Fikrig M., Golden M., Finkelstein F.O. Nine episodes of CPD-associated peritonitis with vancomycin resistant enterococci. Kidney Int 1996; 50: 1368-72.Frieden T.R., Munsiff S.S., Low D.E., Willey B.M., Williams G., Faur Y. et al. Emergence of vancomycin resistant enterococci in New York City. Lancet 1993; 342: 76-9.Frieden T.R., Munsiff S.S., Low D.E., Willey B.M., Williams G., Faur Y. et al. Emergence of vancomycin resistant enterococci in New York City. Lancet 1993; 342: 76-9.Hospital Infection Control Practices Advisory Committee (HICPAC). Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995; 16: 105-13.Hospital Infection Control Practices Advisory Committee (HICPAC). Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995; 16: 105-13.Noble W.C., Virani Z. Cree RGA. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992; 93: 195-8.Noble W.C., Virani Z. Cree RGA. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992; 93: 195-8.Smith T.L., Pearson M.L., Wilcox K.R., Cruz C., Lancaster M.V., Robinson-Dunn B. et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999; 316: 927-31.Smith T.L., Pearson M.L., Wilcox K.R., Cruz C., Lancaster M.V., Robinson-Dunn B. et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999; 316: 927-31.Keane WF. Peritoneal dialysis-related peritonitis treatment recommendations: 1996 update. Perit Dial Int 1996; 16: 557-73.Keane WF. Peritoneal dialysis-related peritonitis treatment recommendations: 1996 update. Perit Dial Int 1996; 16: 557-73.Lai M.-N., Kao M.-T., Chen C.-C., Cheungs S.-Y., Chung W.-K. Intraperitoneal once-daily dose of cefazolin and gentamicin for treating CAPD peritonitis. Perit Dial Int 1997; 17: 87-9.Lai M.-N., Kao M.-T., Chen C.-C., Cheungs S.-Y., Chung W.-K. Intraperitoneal once-daily dose of cefazolin and gentamicin for treating CAPD peritonitis. Perit Dial Int 1997; 17: 87-9.Brown EA., Goldberg LC., Clemenger M., Azadian B. Effective treatment of peritonitis using a once-daily, vancomycin-free regime in CAPD and APD (Abstract). Perit Dial Jnt 1999; 19 (Suppl 1): S30.Brown EA., Goldberg LC., Clemenger M., Azadian B. Effective treatment of peritonitis using a once-daily, vancomycin-free regime in CAPD and APD (Abstract). Perit Dial Jnt 1999; 19 (Suppl 1): S30.Vas S., Bargman J., Oreopoulos D.G. Treatment in PD patients of peritonitis caused by gram-positive organisms with single daily dose of antibiotics. Perit Dial Int 1997; 17: 91-4.Vas S., Bargman J., Oreopoulos D.G. Treatment in PD patients of peritonitis caused by gram-positive organisms with single daily dose of antibiotics. Perit Dial Int 1997; 17: 91-4.Troidle I.K., Gorban-Brcnnan N., KligerA.S., Finkelstein F.O. Peritonitis in the extended care facility. In: Khanna R. ed. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Publications, 1998; 14: 127-30.Troidle I.K., Gorban-Brcnnan N., KligerA.S., Finkelstein F.O. Peritonitis in the extended care facility. In: Khanna R. ed. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Publications, 1998; 14: 127-30.Hashimoto H., Inoue M., Hayashi I. A survey of Staphylococcus aureus for typing and drug-resistance in various areas of Japan during 1992 and 1993. Jpn J Antibiot 1994; 47: 618-26.Hashimoto H., Inoue M., Hayashi I. A survey of Staphylococcus aureus for typing and drug-resistance in various areas of Japan during 1992 and 1993. Jpn J Antibiot 1994; 47: 618-26.Jorgensen J.H. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 4th ed. Approved standard. Wayne, PA: National Committee for Clinical Laboratory Standards, 1997.Jorgensen J.H. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 4th ed. Approved standard. Wayne, PA: National Committee for Clinical Laboratory Standards, 1997.Manley H.J., Bailie G., Asher R.D., Eisele G., Frye R.F. Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1999; 19: 65-70.Manley H.J., Bailie G., Asher R.D., Eisele G., Frye R.F. Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1999; 19: 65-70.Rahal J.J., Urban C., Horn D., Freeman K., SegaI-Maurer S., Maurer J. et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998; 280: 1233-7.Rahal J.J., Urban C., Horn D., Freeman K., SegaI-Maurer S., Maurer J. et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998; 280: 1233-7.Held P.J., Port F.K., Webb R.L. USRDS 1997 annual data report: treatment modalities for ESRD patients. Am J Kidney Dis 1997; 30 (Suppl 1): S54-66.Held P.J., Port F.K., Webb R.L. USRDS 1997 annual data report: treatment modalities for ESRD patients. Am J Kidney Dis 1997; 30 (Suppl 1): S54-66.Troidle L.K., Gorban-Brennan N., Kliger A.S., Finkelstein F.O. Continuous cycler therapy, manual peritoneal dialysis therapy, and peritonitis. In: Khanna R. ed. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Publications, 1998; 14: 137-41.Troidle L.K., Gorban-Brennan N., Kliger A.S., Finkelstein F.O. Continuous cycler therapy, manual peritoneal dialysis therapy, and peritonitis. In: Khanna R. ed. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Publications, 1998; 14: 137-41.Schmidt R., Bender F., Domico J., Bernardini J., Sorkm M., Piraino B. Peritonitis rates of APD may not better those of CAPD (Abstract). Perit Dial Int 1998; 18 (Suppl 1): S34.Schmidt R., Bender F., Domico J., Bernardini J., Sorkm M., Piraino B. Peritonitis rates of APD may not better those of CAPD (Abstract). Perit Dial Int 1998; 18 (Suppl 1): S34.Bunke C.M., Brier M.E., Golper T. Outcomes of.si organism peritonitis in peritoneal dialysis: gram-negatives versus gram-positives in the Network 9 peritonitis study. Kidney Int 1997; 52: 524-9.Bunke C.M., Brier M.E., Golper T. Outcomes of.si organism peritonitis in peritoneal dialysis: gram-negatives versus gram-positives in the Network 9 peritonitis study. Kidney Int 1997; 52: 524-9.Troidle L., Gorban-Brennan N.L.R., Kliger A., Finkelstein F.O. Differing outcomes of gram-positive and gram-negative peritonitis. Am J Kidney Dis 1998; 32: 623-8.Troidle L., Gorban-Brennan N.L.R., Kliger A., Finkelstein F.O. Differing outcomes of gram-positive and gram-negative peritonitis. Am J Kidney Dis 1998; 32: 623-8.Troidle L.K., KligerA.S., Goldie S.J., Gorban-Brennan N., Finkelstein F.O. CPD-associated peritonitis of nosocomial origin. Perit Dial Int 1996; 16: 505-10.Troidle L.K., KligerA.S., Goldie S.J., Gorban-Brennan N., Finkelstein F.O. CPD-associated peritonitis of nosocomial origin. Perit Dial Int 1996; 16: 505-10.WienerJ., Quinn J.P., Bradford P.A., Goering R.V., Nathan C., Bush K. et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999; 281: 517-23.WienerJ., Quinn J.P., Bradford P.A., Goering R.V., Nathan C., Bush K. et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999; 281: 517-23.Lakaye B., Dubus A., Lepage S., Groslnmbert S., Frcre J.-M. When drug inactivation rendors the target irrelevant to antibiotic resistance: a case story with beta-lactams. Mol Microbiol 1999; 31: 89-101.Lakaye B., Dubus A., Lepage S., Groslnmbert S., Frcre J.-M. When drug inactivation rendors the target irrelevant to antibiotic resistance: a case story with beta-lactams. Mol Microbiol 1999; 31: 89-101.Juergensen P., Finkelstein F., Brennan R., Kliger A. Pseudomonas peritonitis associated with continuous ambulatory peritoneal dialysis: a six year study. Am J Kidney Dis 1988; 11: 1413-17.Juergensen P., Finkelstein F., Brennan R., Kliger A. Pseudomonas peritonitis associated with continuous ambulatory peritoneal dialysis: a six year study. Am J Kidney Dis 1988; 11: 1413-17.Luzar M.A., Coles G., Faller B., Slingencyer A., Dah Dah G., Briat C. et al. Staphylococcus aureus nasal carriage and infection in patients on continuous ambulatory peritoneal dialysis. N Engl J Med 1990; 322: 505-9.Luzar M.A., Coles G., Faller B., Slingencyer A., Dah Dah G., Briat C. et al. Staphylococcus aureus nasal carriage and infection in patients on continuous ambulatory peritoneal dialysis. N Engl J Med 1990; 322: 505-9.Piraino B. A review of Staphylococcus aureus exit-site and tunnel infections in peritoneal dialysis patients. Kidney Dis 1990; 16: 89-95.Piraino B. A review of Staphylococcus aureus exit-site and tunnel infections in peritoneal dialysis patients. Kidney Dis 1990; 16: 89-95.Bernardini J., Piraino B., Holley J., Johnston J.R., Lutes R. A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cycli oral rifampin. Am J Kidney Dis 1996; 27: 695-700.Bernardini J., Piraino B., Holley J., Johnston J.R., Lutes R. A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cycli oral rifampin. Am J Kidney Dis 1996; 27: 695-700.Thodis E., Bhaskaran S., Pasadakis P., Bargman J.M., Vas S.I., Oreopoulos D.G. Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site. Perit Dial Int 1998; 18: 261-70.Thodis E., Bhaskaran S., Pasadakis P., Bargman J.M., Vas S.I., Oreopoulos D.G. Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site. Perit Dial Int 1998; 18: 261-70.Goldie S.J., Kiernan-Troidle L., Torres C., Gorban-Brennan N., Dunne D., Kliger A.S. et al. Fungal peritonitis in a large chronic peritoneal dialysis population: a report of 55 episodes. Am J Kidney Dis 1996; 28: 86-91.Goldie S.J., Kiernan-Troidle L., Torres C., Gorban-Brennan N., Dunne D., Kliger A.S. et al. Fungal peritonitis in a large chronic peritoneal dialysis population: a report of 55 episodes. Am J Kidney Dis 1996; 28: 86-91.Lo W.-K., Chan C.-Y., Cheng S.-W., Poon J.F.-M., C’han D.T.-M., Cheng I.K.-P. A prospective randomized control study of oral nystatin prophylaxis for candida peritonitis complicating continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1996; 28: 549-52.Lo W.-K., Chan C.-Y., Cheng S.-W., Poon J.F.-M., C’han D.T.-M., Cheng I.K.-P. A prospective randomized control study of oral nystatin prophylaxis for candida peritonitis complicating continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1996; 28: 549-52.Thodis E., Vas S.I., Bargman J.M., Singhal M., Chu M., Oreopoulos D.G. Nystatin prophylaxis: its inability to prevent fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 1998; 18: 583-9.Thodis E., Vas S.I., Bargman J.M., Singhal M., Chu M., Oreopoulos D.G. Nystatin prophylaxis: its inability to prevent fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 1998; 18: 583-9.

The authors declare that there are no conflicts of interest present.